PrioThera is a clinical stage pharma company developing a non-immunosuppressive molecule for the treatment of high-risk acute myeloid leukaemia (AML). Today, at least 30,000 Hematopoietic Stem Cell Transplantation (HSCT) procedures are performed on AML patients every year worldwide, with acute graft-versus-host disease (GvHD) remaining the major complication of HSCT. S1P receptor (S1PR) modulators have been shown to largely reduce the egress of T-cell subsets from lymphatic tissues and are thereby suggested to inhibit GvHD while at the same time enhancing graft-versus-leukemia benefits in patients receiving allogeneic HSCT. Priothera is developing mocravimod (KRP-203), a S1PR modulator, to enhance the curative potential of allogeneic HSCT. Mocravimod has been extensively tested in multiple immunological models and has shown a survival benefit and reduced severity of GvHD in a clinical study evaluating acute myeloid leukemia and acute lymphoblastic leukemia (ALL) patients undergoing allogeneic HSCT.
Total raised: $55.3M
Investors 3
| Date | Name | Website |
| 05.03.2021 | Earlybird ... | earlybird.... |
| 26.06.2022 | HealthCap | healthcap.... |
| 14.09.2023 | Fountain H... | fh-partner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.02.2022 | - | $19.87M | - |
| 13.10.2020 | Series A | $35.44M | - |
Mentions in press and media 25
| Date | Title | Description | Source |
| 22.04.2024 | Earlybird Health's ESG report one year on: how can VCs optim... | With €2 billion of assets under management across all fund streams, nine IPOs and 33 trade sales, Ea... | tech.eu/20... |
| 14.02.2024 | Earlybird Health closes twice-larger second fund, will write... | Germany-based Earlybird Health announced the final closing of its second fund of €173 million (aroun... | techcrunch... |
| 27.11.2023 | US FDA grants Orphan Drug Designation to mocravimod to imp... | Mocravimod is the only S1P receptor modulator being developed as an adjunctive and maintenance treat... | fh-partner... |
| 24.01.2023 | Priothera announces first patients enrolled in pivotal MO-TR... | Dublin, Ireland – January 23, 2023 – Priothera, a late-clinical stage biotechnology company pioneeri... | healthcap.... |
| 23.01.2023 | Priothera announces first patients enrolled in pivotal MO-TR... | Mocravimod is the only S1PR modulator being developed to treat blood cancers and improve CAR-T thera... | einpresswi... |
| 23.01.2023 | Priothera announces first patients enrolled in pivotal MO-... | Mocravimod is the only S1PR modulator being developed to treat blood cancers and improve CAR-T thera... | fh-partner... |
| 01.06.2022 | Priothera Receives Fast Track Designation for mocravimod i... | Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P recepto... | fh-partner... |
| 25.04.2022 | Priothera to present an abstract at the TANDEM Meetings / Tr... | The success of allogeneic hematopoietic stem cell transplantation (HSCT) is limited by disease relap... | healthcap.... |
| 25.04.2022 | Priothera Receives FDA clearance of IND to start Phase 2b/... | Priothera Ltd, a late-clinical stage biotechnology company pioneering the development of its S1P r... | fh-partner... |
| 12.04.2022 | Priothera Receives First Regulatory Approvals to Start a G... | Priothera Ltd, a late-clinical stage biotechnology company pioneering the development of its S1P r... | fh-partner... |
Show more